Anglo-Swedish drug major AstraZeneca says that new data demonstrate that the addition of 150mg Casodex (bicalutamide) to radiotherapy reduces the risk of death by 35% in men with locally-advanced prostate cancer compared to radiotherapy alone (p = 0.03).
According to the firm, the findings, published in the February edition of the British Journal of Urology, provide the first evidence of an overall survival benefit for treating locally-advanced prostate cancer with adjuvant hormonal therapy, which is not based on castration.
These data are important as up to 43% of men with locally-advanced disease who receive treatment with radiotherapy alone, traditionally the treatment of choice, die within five years of therapy.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze